BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaibar M, Beltrán L, Romero-Lorca A, Fernández-Santander A, Novillo A. Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer. J Oncol 2020;2020:6375956. [PMID: 32256585 DOI: 10.1155/2020/6375956] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Eliseeva OA, Kolganova MA, Shokhin IE, Dementyev SP, Vlasov AM, Zamyatnin AA, Dubovik NS, Savchenko AY, Dozmorova NV, Luzhanin VG. Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum. Razrabotka i registraciâ lekarstvennyh sredstv 2022;11:120-127. [DOI: 10.33380/2305-2066-2022-11-4(1)-120-127] [Reference Citation Analysis]
2 Singh DD, Lee HJ, Yadav DK. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Front Pharmacol 2022;13:1089066. [PMID: 36578543 DOI: 10.3389/fphar.2022.1089066] [Reference Citation Analysis]
3 Bergado-báez G, Gonzalez Suarez N, García LC, Pérez-martínez D, Hernández-fernández DR, Fundora-barrios T, Rodríguez-álvarez A, Díaz-ordaz GD, Lindzen M, Yarden Y, Sánchez-ramírez B. Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.951267] [Reference Citation Analysis]
4 Guan Y, Wang Y, Li H, Meng J, You X, Zhu X, Zhang Q, Sun T, Qi C, An G, Fan Y, Xu B. Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. Front Oncol 2022;12:986674. [DOI: 10.3389/fonc.2022.986674] [Reference Citation Analysis]
5 Asgari-Karchekani S, Aryannejad A, Mousavi SA, Shahsavarhaghighi S, Tavangar SM. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. Med Oncol 2022;39:210. [PMID: 36175719 DOI: 10.1007/s12032-022-01817-6] [Reference Citation Analysis]
6 Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
7 Li S, Liu Q, Liu M, Liu T. . CMAR 2022;Volume 14:2927-32. [DOI: 10.2147/cmar.s365951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wang D, Chen X, Du Y, Li X, Ying L, Lu Y, Shen B, Gao X, Yi X, Xia X, Sui X, Shu Y. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. Front Immunol 2022;13:799988. [PMID: 35281032 DOI: 10.3389/fimmu.2022.799988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wynn CS, Tang SC. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer Metastasis Rev 2022. [PMID: 35142964 DOI: 10.1007/s10555-022-10021-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Roshanian Bakhsh M, Peymani M, Rouhi L, Ghaedi K. PSAT1 gene as a biomarker for targeting triple negative breast cancer in presence of Rapamycin. Nucleosides, Nucleotides & Nucleic Acids 2022;41:166-182. [DOI: 10.1080/15257770.2021.2025393] [Reference Citation Analysis]
11 Colarusso C, Terlizzi M, Pinto A, Sorrentino R. Drug Resistance in Lung Cancer. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_62] [Reference Citation Analysis]
12 Gao Z, Xu J, Wang Y, Wu J, Sun T. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant. Front Oncol 2021;11:715554. [PMID: 34722261 DOI: 10.3389/fonc.2021.715554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Guerrero-esteban T, Gutiérrez-sánchez C, García-mendiola T, Revenga-parra M, Pariente F, Lorenzo E. Bifunctional carbon nanodots for highly sensitive HER2 determination based on electrochemiluminescence. Sensors and Actuators B: Chemical 2021;343:130096. [DOI: 10.1016/j.snb.2021.130096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
14 Sun L, Wu A, Bean GR, Hagemann IS, Lin CY. Molecular Testing in Breast Cancer: Current Status and Future Directions. J Mol Diagn 2021;23:1422-32. [PMID: 34454106 DOI: 10.1016/j.jmoldx.2021.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ross DS, Pareja F. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations. Surg Pathol Clin 2021;14:455-71. [PMID: 34373096 DOI: 10.1016/j.path.2021.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Novillo A, Fernández-Santander A, Gaibar M, Galán M, Romero-Lorca A, El Abdellaoui-Soussi F, Gómez-Del Arco P. Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer. Front Oncol 2021;11:633233. [PMID: 33981601 DOI: 10.3389/fonc.2021.633233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gameiro A, Nascimento C, Correia J, Ferreira F. HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. Cancers (Basel) 2021;13:2007. [PMID: 33919468 DOI: 10.3390/cancers13092007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Michele G, Giuseppe T, Anders H. Molecular mechanisms of YY1 overexpression in human cancers and its prognostic significance. YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer 2021. [DOI: 10.1016/b978-0-12-821909-6.00015-8] [Reference Citation Analysis]
19 Weng C, Yang T, Li Y. Design and fabrication of cell-targeted, dual drug-loaded nanoparticles with pH-controlled drug release and near-infrared light-induced photothermal effects. Materials & Design 2021;197:109230. [DOI: 10.1016/j.matdes.2020.109230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Bajpai M, (David) Zhou Z. Biomarkers of Esophageal Cancers and Precancerous Lesions. Physiology in Health and Disease 2021. [DOI: 10.1007/978-3-030-67951-4_5] [Reference Citation Analysis]
21 Szymiczek A, Lone A, Akbari MR. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin Genet 2021;99:613-37. [PMID: 33340095 DOI: 10.1111/cge.13900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]